Our services are centred around intellectual property that can be registered. We protect innovation, design, and branding across all sectors of industry, and at all stages in the supply chain.

For each IP right we offer services covering strategic advice, pre-registration searches, registrations and renewals, oppositions and dispute resolution. We handle work throughout the world, working with local colleagues in over 100 countries.


Our attorneys specialise in one or more sectors of industry, which enables them to provide quality advice with a commercial focus.

Our patent specialists have detailed understanding of the background technology, which ensures that your patent applications are prepared with the correct scope, reducing the likelihood of challenges from third parties and objections from the patent office.

They also advise whether other forms of protection would be more appropriate. Our brand specialists work with brand managers for leading brands and their advice is commercially focussed making sure that you get the best value from your budget.

Should drug trials be allowed without the risk of patent infringement?


On 24th October 2012, the UK Intellectual Property Office (IPO) launched a formal consultation on proposals to amend the Patents Act. The proposed changes would allow clinical and field trials for new drugs to be carried out without the risk of patent infringement. The proposal is of course relevant to patent holders in the pharmaceutical field.

The proposal is also relevant to organisations undertaking clinical or field trials in the UK, such as pharmaceutical companies, and clinical research organisations etc, who undertake trials on behalf of clients. This formal consultation is in response to concerns by these organisations, that the current UK regulatory framework puts them at risk of patent infringement when running clinical or field trials. This in turn results in an unwillingness to conduct them in the UK.

The consultation document can be found here and it is possible to comment on the proposal submit comments via annex B of the document. The deadline for submitting comments is 19th December 2012.

This article is for general information only. Its content is not a statement of the law on any subject and does not constitute advice. Please contact Reddie & Grose LLP for advice before taking before any action in reliance on it.

Saved Staff
Staff member

Remove all

Call +44 (0)20 7242 0901
Call +44 (0)1223 360 350
Call +49 (0) 89 206054 267
Call +(00) 31 70 800 2162
This field is for validation purposes and should be left unchanged.